Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Resequencing Study Confirms Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Soon Kim D, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Montes Worboys A, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstrong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Apr 29. doi: 10.1164/rccm.201810-1891OC. [Epub ahead of print]

2.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

3.

The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.

Hammond M, Clark AB, Cahn AP, Chilvers ER, Fraser WD, Livermore DM, Maher TM, Parfrey H, Swart AM, Stirling S, Thickett D, Whyte M, Wilson A.

Trials. 2018 Feb 5;19(1):89. doi: 10.1186/s13063-018-2453-6.

4.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG.

Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14.

5.

Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.

Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, Guillen-Guio B, Ma SF, Okamoto T, John AE, Obeidat M, Yang IV, Henry A, Hubbard RB, Navaratnam V, Saini G, Thompson N, Booth HL, Hart SP, Hill MR, Hirani N, Maher TM, McAnulty RJ, Millar AB, Molyneaux PL, Parfrey H, Rassl DM, Whyte MKB, Fahy WA, Marshall RP, Oballa E, Bossé Y, Nickle DC, Sin DD, Timens W, Shrine N, Sayers I, Hall IP, Noth I, Schwartz DA, Tobin MD, Wain LV, Jenkins RG.

Lancet Respir Med. 2017 Nov;5(11):869-880. doi: 10.1016/S2213-2600(17)30387-9. Epub 2017 Oct 20.

6.

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM.

Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2.

7.

Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis.

Fiddler CA, Simler N, Parfrey H, Miremadi A, Chilvers ER.

Ann Am Thorac Soc. 2016 Aug;13(8):1430-2. doi: 10.1513/AnnalsATS.201602-118LE. No abstract available.

PMID:
27509160
8.

Amplification of TGFβ Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis.

Tatler AL, Goodwin AT, Gbolahan O, Saini G, Porte J, John AE, Clifford RL, Violette SM, Weinreb PH, Parfrey H, Wolters PJ, Gauldie J, Kolb M, Jenkins G.

PLoS One. 2016 Aug 5;11(8):e0158047. doi: 10.1371/journal.pone.0158047. eCollection 2016.

9.

The Aminopeptidase CD13 Induces Homotypic Aggregation in Neutrophils and Impairs Collagen Invasion.

Fiddler CA, Parfrey H, Cowburn AS, Luo D, Nash GB, Murphy G, Chilvers ER.

PLoS One. 2016 Jul 28;11(7):e0160108. doi: 10.1371/journal.pone.0160108. eCollection 2016.

10.

Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin αvβ6 Expression.

Tatler AL, Habgood A, Porte J, John AE, Stavrou A, Hodge E, Kerama-Likoko C, Violette SM, Weinreb PH, Knox AJ, Laurent G, Parfrey H, Wolters PJ, Wallace W, Alberti S, Nordheim A, Jenkins G.

J Biol Chem. 2016 Apr 29;291(18):9540-53. doi: 10.1074/jbc.M115.692368. Epub 2016 Feb 9.

11.

Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique.

Maher TM, Whyte MK, Hoyles RK, Parfrey H, Ochiai Y, Mathieson N, Turnbull A, Williamson N, Bennett BM.

Adv Ther. 2015 Oct;32(10):929-43. doi: 10.1007/s12325-015-0249-6. Epub 2015 Oct 23.

12.

Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial.

Wilson EC, Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Twentyman OP, Wilson AM.

Pharmacoeconomics. 2014 Jan;32(1):87-99. doi: 10.1007/s40273-013-0112-z.

PMID:
24307539
13.

Author's response: co-trimoxazole treatment in idiopathic pulmonary fibrosis.

Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson EC, Twentyman OP, Davison AG, Curtin JJ, Crawford MB, Wilson AM.

Thorax. 2013 Sep;68(9):884-5. doi: 10.1136/thoraxjnl-2013-203765. Epub 2013 Jun 21. No abstract available.

PMID:
23935173
14.

Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.

Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson EC, Twentyman OP, Davison AG, Curtin JJ, Crawford MB, Wilson AM.

Thorax. 2013 Feb;68(2):155-62. doi: 10.1136/thoraxjnl-2012-202403. Epub 2012 Nov 10.

PMID:
23143842
15.

The pathogenesis of pulmonary fibrosis: a moving target.

Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V, Egan JJ, Lambrecht BN, Lories R, Parfrey H, Prasse A, Robalo-Cordeiro C, Verbeken E, Verschakelen JA, Wells AU, Verleden GM.

Eur Respir J. 2013 May;41(5):1207-18. doi: 10.1183/09031936.00073012. Epub 2012 Oct 25. Review.

16.

A hybrid single-trocar VATS technique for extracorporeal wedge biopsy of the lingula in patients with diffuse lung disease.

Migliore M, Criscione A, Parfrey H.

Updates Surg. 2012 Sep;64(3):223-5. doi: 10.1007/s13304-012-0160-5. Epub 2012 May 29.

PMID:
22644718
17.

Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes.

Reddy TL, Tominaga M, Hansell DM, von der Thusen J, Rassl D, Parfrey H, Guy S, Twentyman O, Rice A, Maher TM, Renzoni EA, Wells AU, Nicholson AG.

Eur Respir J. 2012 Aug;40(2):377-85. doi: 10.1183/09031936.00165111. Epub 2012 Mar 22.

18.

Non-infectious pulmonary toxicity of rituximab: a systematic review.

Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ.

Rheumatology (Oxford). 2012 Apr;51(4):653-62. doi: 10.1093/rheumatology/ker290. Epub 2011 Dec 7. Review.

PMID:
22157468
19.

The serpinopathies studying serpin polymerization in vivo.

Irving JA, Ekeowa UI, Belorgey D, Haq I, Gooptu B, Miranda E, Pérez J, Roussel BD, Ordóñez A, Dalton LE, Thomas SE, Marciniak SJ, Parfrey H, Chilvers ER, Teckman JH, Alam S, Mahadeva R, Rashid ST, Vallier L, Lomas DA.

Methods Enzymol. 2011;501:421-66. doi: 10.1016/B978-0-12-385950-1.00018-3.

PMID:
22078544
20.

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.

Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ.

Rheumatology (Oxford). 2011 Dec;50(12):2297-305. doi: 10.1093/rheumatology/ker289. Epub 2011 Oct 22. Review.

PMID:
22019799
21.

In search of the fibrotic epithelial cell: opportunities for a collaborative network.

Jenkins G, Blanchard A, Borok Z, Bradding P, Ehrhardt C, Fisher A, Hirani N, Johnson S, Königshoff M, Maher TM, Millar A, Parfrey H, Scotton C, Tetley T, Thickett D, Wolters P; ECIPF workshop.

Thorax. 2012 Feb;67(2):179-82. doi: 10.1136/thoraxjnl-2011-200195. Epub 2011 Jun 15.

PMID:
21680569
22.

Potential biomarkers of monocyte/macrophage activity in a patient with sarcoidosis, treated with infliximab.

Fang B, Bhagat S, Busch R, Parfrey H, Hall FC.

Rheumatology (Oxford). 2011 May;50(5):992-4. doi: 10.1093/rheumatology/keq449. Epub 2011 Jan 27. No abstract available.

PMID:
21278065
23.

TNF receptor-1 (TNF-R1) ubiquitous scaffolding and signaling protein interacts with TNF-R1 and TRAF2 via an N-terminal docking interface.

Terry Powers JL, Mace KE, Parfrey H, Lee SJ, Zhang G, Riches DW.

Biochemistry. 2010 Sep 14;49(36):7821-9. doi: 10.1021/bi100726n.

24.

Live and let die: is neutrophil apoptosis defective in severe asthma?

Parfrey H, Farahi N, Porter L, Chilvers ER.

Thorax. 2010 Aug;65(8):665-7. doi: 10.1136/thx.2009.134270. No abstract available.

PMID:
20685738
25.

TRUSS, TNF-R1, and TRPC ion channels synergistically reverse endoplasmic reticulum Ca2+ storage reduction in response to m1 muscarinic acetylcholine receptor signaling.

Mace KE, Lussier MP, Boulay G, Terry-Powers JL, Parfrey H, Perraud AL, Riches DW.

J Cell Physiol. 2010 Nov;225(2):444-53. doi: 10.1002/jcp.22221.

26.

Idiopathic pulmonary fibrosis in a Christmas Island nuclear test veteran.

Parfrey H, Babar J, Fiddler CA, Chilvers ER.

BMJ Case Rep. 2010 Nov 23;2010. pii: bcr0620103102. doi: 10.1136/bcr.06.2010.3102.

27.

Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology.

Lomas DA, Parfrey H.

Thorax. 2004 Jun;59(6):529-35. Review.

28.

Inhibiting polymerization: new therapeutic strategies for Z alpha1-antitrypsin-related emphysema.

Parfrey H, Dafforn TR, Belorgey D, Lomas DA, Mahadeva R.

Am J Respir Cell Mol Biol. 2004 Aug;31(2):133-9. Epub 2004 Mar 11.

PMID:
15016619
29.

Targeting a surface cavity of alpha 1-antitrypsin to prevent conformational disease.

Parfrey H, Mahadeva R, Ravenhill NA, Zhou A, Dafforn TR, Foreman RC, Lomas DA.

J Biol Chem. 2003 Aug 29;278(35):33060-6. Epub 2003 Jun 13.

30.

Alpha(1)-antitrypsin deficiency, liver disease and emphysema.

Parfrey H, Mahadeva R, Lomas DA.

Int J Biochem Cell Biol. 2003 Jul;35(7):1009-14. Review.

PMID:
12672469
31.

Prevention of polymerization of M and Z alpha1-Antitrypsin (alpha1-AT) with trimethylamine N-oxide. Implications for the treatment of alpha1-at deficiency.

Devlin GL, Parfrey H, Tew DJ, Lomas DA, Bottomley SP.

Am J Respir Cell Mol Biol. 2001 Jun;24(6):727-32.

PMID:
11415938
32.

Pleural disease--diagnosis and management.

Parfrey H, Chilvers ER.

Practitioner. 1999 May;243(1598):412, 415-21. Review. No abstract available.

PMID:
10534890

Supplemental Content

Loading ...
Support Center